학술논문
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Document Type
article
Author
Young-Suk Lim; Henry L.Y. Chan; Sang Hoon Ahn; Wai Kay Seto; Qin Ning; Kosh Agarwal; Harry L.A. Janssen; Calvin Q. Pan; Wan Long Chuang; Namiki Izumi; Scott Fung; Shalimar; Maurizia Brunetto; Aric Josun Hui; Ting-Tsung Chang; Seng Gee Lim; Frida Abramov; John F. Flaherty; Hongyuan Wang; Leland J. Yee; Jia-Horng Kao; Edward Gane; Jinlin Hou; Maria Buti
Source
JHEP Reports, Vol 5, Iss 10, Pp 100847- (2023)
Subject
Language
English
ISSN
2589-5559
Abstract
Background & Aims: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. Methods: The REACH-B, aMAP, and mPAGE-B models were utilized to assess HCC risk in patients with CHB from two global randomized-controlled trials evaluating the impact of TAF vs. TDF treatment. Standard incidence ratios (SIRs) were calculated using data from the REACH-B model as a ratio of observed HCC cases in the TAF- or TDF-treated patients vs. predicted HCC cases for untreated historical controls. Proportions of treated patients shifting aMAP and mPAGE-B risk categories between baseline and Week 240 were calculated. Results: Of the 1,632 patients (TAF, n = 1,093; TDF, n = 539) followed for up to 300 weeks, 22 HCC cases developed. Those receiving TAF had an SIR that was lower compared to the SIR of individuals receiving TDF: 0.32 (p